Extra Lives: Access to Knowledge ( A2K ) vs. exclusive regimes
Keywords:
A2K, life-sciences, exclusive rights regimes, patents, genericsAbstract
The ratcheting up of global patent standards, fuelled by technology-exporting countries under the pressure of industry lobbies, erodes access to affordable drugs in the developing world. In response to increasing tensions with developing countries and A2K (Access to Knowledge) advocates, the TRIPS agreement was partially reengineered. As a result, a re-regulation process took place suspending key treaty provisions -article 31(f)-, and erecting a burdensome mechanism for importing generics under compulsory license. Reasonably, more effective policy options are still available.
Downloads
Downloads
Published
Issue
Section
License
Eunomía. Revista en Cultura de la Legalidad is a duly registered journal, with EISSN 2253-6655.
The articles published in Eunomía are –unless indicated otherwise– under a Creative Commons Attribution-No Derivative Works 3.0 Spain license. You can copy, distribute and communicate them publicly as long as you cite their author and the journal and institution that publishes them and do not make derivative works with them. The full license can be consulted at: http://creativecommons.org/licenses/by-nd/3.0/es/deed.es